Stock Financial Ratios, Dividends, Split History

TREE / LendingTree, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,897.88
Enterprise Value ($M)2,792.74
Book Value ($M)329.90
Book Value / Share26.41
Price / Book8.78
NCAV ($M)52.17
NCAV / Share4.18
Price / NCAV55.54
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 13,682,000
Common Stock Shares Outstanding 11,979,434
Common Shares Outstanding 12,243,752
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 11,945,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)n/a
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio3.33
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Revenue-750,000.00
Operating Income33.13
Earnings Per Share Basic And Diluted0.00
Earnings Per Share Diluted1.14
Earnings Per Share Basic1.30
Cash Flow Statement (mra) ($M)
Cash From Operations103.54
Cash from Investing-74.44
Cash from Financing103.54
Identifiers and Descriptors
Central Index Key (CIK)1434621
Related CUSIPS
894675107 52603B907 52603B957
Industry Groups
SIC 6163 - Loan Brokers

Split History

Stock splits are used by LendingTree, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

EverQuote IPO: Provides Traffic To Geico, But Without Revenue Generation It Is Not A Buy

2018-07-05 seekingalpha
The company trades at 3.1x its sales, and its competitor LendingTree is trading at more than 7.14x its sales. (6-0)

LendingTree Completes Acquisition of Ovation Credit Services

2018-06-13 zacks
LendingTree (TREE - Free Report) recently announced that it has closed the deal to acquire Ovation Credit Services through its subsidiary, LendingTree, LLC. The companies had entered into agreement on May 11, 2018, for a total consideration of $20.75 million. Ovation Credit Services is a leading provider of credit repair process through its proprietary software application that is integrated directly with certain credit bureaus. (44-0)

5 Worst-Performing Finance Sector Stocks to Steer Clear Of

2018-05-15 zacks
The Finance sector, which has been in the spotlight since the U.S. Presidential elections in November 2016, reported impressive first-quarter 2018 results. Per the latest Earnings Preview, the S&P 500 finance stocks recorded 24.7% year-over-year earnings improvement. This was mainly driven by favorable macroeconomic factors, higher interest rates, decent loan and deposit growth, and lower tax rates. (77-2)

7 Stocks to Buy That Lost 10% in April

2018-05-09 investorplace
I happened to read a May 4 article discussing the reasons why Bed Bath & Beyond Inc. (NASDAQ:BBBY) lost 17% of its value in the month of April — BBBY hasn’t had a positive annual return since 2013 — and it got me thinking about other potential stocks to buy that lost ground last month. (299-4)

Merck Is Inexpensive - Cramer's Lightning Round (5/7/18)

2018-05-08 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, May 7. (174-0)

CUSIP: 52603B107